4D Molecular Therapeutics Set to Shine at the 2024 Cystic Fibrosis Conference
EMERYVILLE, Calif. – 4D Molecular Therapeutics (NASDAQ: FDMT), a trailblazer in genetic medicine, is preparing for a key presentation at the upcoming 2024 North American Cystic Fibrosis Conference (NACFC). This exciting event will take place in Boston from September 26-28, where 4DMT will highlight its recent advancements.
Overview of the 2024 NACFC Presentation
4DMT is thrilled to present a compelling poster titled "Transgene expression and CFTR channel function in human bronchial epithelial cells following addition of CFTR modulators and 4D-710." This presentation will explore innovative solutions that have the potential to improve treatment methods for cystic fibrosis.
Details on the Poster Session
You can find their poster featured in Poster Session 344. Attendees are encouraged to stop by and discover more about the groundbreaking work being done by 4D Molecular Therapeutics.
When to Attend the Presentation
Don’t forget to mark your calendar for Friday, September 27, 2024, from 1:15 to 2:15 p.m. ET. Dr. Melissa A. Calton, the VP of Early-Stage Product Development, and her team will be present to discuss their findings and address any questions you may have.
About 4D Molecular Therapeutics
4DMT focuses on developing clinical-stage genetic medicines aimed at tackling complex diseases in vital areas like ophthalmology and pulmonology. Their innovative Therapeutic Vector Evolution platform uses cutting-edge directed evolution technology, incorporating around one billion synthetic AAV capsid-derived sequences to create tailored vectors that enhance treatment effectiveness.
Innovative Product Pipeline
With a strong pipeline that features six clinical-stage products and one in preclinical development, 4DMT is working on therapies designed for both rare and common diseases across multiple medical fields, such as cardiology and central nervous system disorders.
Dedication to Progress
The company is deeply committed to transforming medicine through potentially curative therapies. Their continuous advancements offer hope for millions struggling with genetic disorders.
Future Vision and Directions
4DMT aims not only to create effective therapies but also to ensure that these treatments reach the patients who need them the most. Their ongoing research and development initiatives focus on delivering innovative and effective solutions to the market, offering long-lasting treatments for various genetically related diseases.
Contact Information
If you have any questions or need more information, please reach out to:
Media Contact:
Katherine Smith
Inizio Evoke Comms
Media@4DMT.com
Investor Relations:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
Frequently Asked Questions
What is the focus of 4D Molecular Therapeutics?
4DMT is dedicated to creating genetic medicines targeting various diseases, especially in the fields of ophthalmology and pulmonology.
When and where is 4DMT presenting?
4DMT will be presenting at the 2024 North American Cystic Fibrosis Conference from September 26-28 in Boston.
What is the title of 4DMT's presentation?
The title of the presentation is "Transgene expression and CFTR channel function in human bronchial epithelial cells following addition of CFTR modulators and 4D-710."
Who will be presenting at the conference?
The presentation will be led by Dr. Melissa A. Calton, who serves as the VP of Early-Stage Product Development at 4DMT.
How can I learn more about 4DMT?
You can visit 4D Molecular Therapeutics’ website to find more information about their ongoing projects, recent news, and advancements.